$1.30
0.00% day before yesterday
Nasdaq, May 30, 07:01 pm CET
ISIN
US00972G1085
Symbol
AKTX
Sector
Industry

Akari Therapeutics Plc Sponsored ADR Stock price

$1.35
-0.09 6.25% 1M
-0.01 0.74% 6M
+0.13 10.66% YTD
-0.37 21.28% 1Y
-22.45 94.33% 3Y
-42.65 96.93% 5Y
-84.67 98.43% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.05 3.85%
ISIN
US00972G1085
Symbol
AKTX
Sector
Industry

Key metrics

Market capitalization $37.54m
Enterprise Value $38.20m
EV/FCF (TTM) EV/FCF negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-17.69m
Free Cash Flow (TTM) Free Cash Flow $-12.55m
Cash position $2.60m
EPS (TTM) EPS $0.00
Short interest 0.57%

Is Akari Therapeutics Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Akari Therapeutics Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:

Buy
100%

Financial data from Akari Therapeutics Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
38% 38%
-
- Research and Development Expense 6.98 6.98
20% 20%
-
-18 -18
32% 32%
-
- Depreciation and Amortization 0.01 0.01
-
-
EBIT (Operating Income) EBIT -18 -18
32% 32%
-
Net Profit -20 -20
52% 52%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akari Therapeutics Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akari Therapeutics Plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
3 days ago
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates
Neutral
GlobeNewsWire
10 days ago
BOSTON and LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29...
Neutral
GlobeNewsWire
13 days ago
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
More Akari Therapeutics Plc Sponsored ADR News

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Abizer Gaslightwala
Employees 9
Founded 2004
Website www.akaritx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today